You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

tricor Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tricor, and what generic alternatives are available?

Tricor is a drug marketed by Abbvie and is included in three NDAs.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tricor

A generic version of tricor was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for tricor?
  • What are the global sales for tricor?
  • What is Average Wholesale Price for tricor?
Drug patent expirations by year for tricor
Drug Prices for tricor

See drug prices for tricor

Drug Sales Revenue Trends for tricor

See drug sales revenues for tricor

Recent Clinical Trials for tricor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lindsay Ferguson, MDPhase 1
Shriners Hospitals for ChildrenPhase 2/Phase 3
National Institute of General Medical Sciences (NIGMS)Phase 2/Phase 3

See all tricor clinical trials

Pharmacology for tricor
Paragraph IV (Patent) Challenges for TRICOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRICOR Tablets fenofibrate 48 mg 021656 1 2008-07-01
TRICOR Tablets fenofibrate 145 mg 021656 1 2007-10-19

US Patents and Regulatory Information for tricor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR (MICRONIZED) fenofibrate CAPSULE;ORAL 019304-004 Jun 30, 1999 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for tricor

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ⤷  Sign Up ⤷  Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for tricor

See the table below for patents covering tricor around the world.

Country Patent Number Title Estimated Expiration
Germany 60121570 ⤷  Sign Up
Denmark 0499299 ⤷  Sign Up
South Korea 20050026705 NANOPARTICULATE FIBRATE FORMULATIONS ⤷  Sign Up
New Zealand 228130 THERAPEUTIC COMPOSITION COMPRISING FENOFIBRATE AND A SOLID SURFACTANT WHICH HAS BEEN CO-MICRONISED; PREPARATORY PROCESS ⤷  Sign Up
Cyprus 2396 Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.